Publications by authors named "Kevin Guertin"

Claim this Profile
P
PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy.
Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Kevin R Guertin

J Exp Med· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unleashing the Power of NR4A1 Degradation as a Novel Strategy for Cancer Immunotherapy.
Lei Wang, Yufeng Xiao, Yuewan Luo, Rohan P Master, Jiao Mo, Kevin R Guertin

bioRxiv· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MetAP2 inhibition modifies hemoglobin S to delay polymerization and improves blood flow in sickle cell disease.
Melanie Demers, Sarah Sturtevant, Kevin R Guertin, Dipti Gupta, Kunal Desai

Blood Adv· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small molecule mediated inhibition of RORγ-dependent gene expression and autoimmune disease pathology in vivo.
Daliya Banerjee, Linlin Zhao, Lan Wu, Arumugam Palanichamy, Ayla Ergun, Kevin Guertin

Immunology· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel pyrazole-containing benzamides as potent RORγ inverse agonists.
Tao Wang, Daliya Banerjee, Tonika Bohnert, Jianhua Chao, Istvan Enyedy, Kevin Guertin

Bioorg Med Chem Lett· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of biaryl carboxylamides as potent RORγ inverse agonists.
Jianhua Chao, Istvan Enyedy, Kurt Van Vloten, Douglas Marcotte, Kevin Guertin

Bioorg Med Chem Lett· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of camphor-derived pyrazolones as 11β-hydroxysteroid dehydrogenase type 1 inhibitors.
Paul Gillespie, Sherrie Pietranico-Cole, Michael Myers, Joseph A Bilotta, Karin Conde-Knape, Kevin R Guertin

Bioorg Med Chem Lett· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of RO4597014, a Glucokinase Activator Studied in the Clinic for the Treatment of Type 2 Diabetes.
Yimin Qian, Wendy L Corbett, Steven J Berthel, Duk Soon Choi, Mark T Dvorozniak, Kevin R Guertin

ACS Med Chem Lett· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
Ramakanth Sarabu, Fred T Bizzarro, Wendy L Corbett, Mark T Dvorozniak, Wanping Geng, Kevin R Guertin

J Med Chem· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
4
4-Substituted-7-N-alkyl-N-acetyl 2-aminobenzothiazole amides: drug-like and non-xanthine based A2B adenosine receptor antagonists.
Adrian Wai-Hing Cheung, John Brinkman, Fariborz Firooznia, Alexander Flohr, Joseph Grimsby, Kevin Guertin

Bioorg Med Chem Lett· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery, structure-activity relationships, pharmacokinetics, and efficacy of glucokinase activator (2R)-3-cyclopentyl-2-(4-methanesulfonylphenyl)-N-thiazol-2-yl-propionamide (RO0281675).
Nancy-Ellen Haynes, Wendy L Corbett, Fred T Bizzarro, Kevin R Guertin, Darryl W Hilliard

J Med Chem· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of the Factor Xa inhibitor otamixaban: from lead identification to clinical development.
Kevin R Guertin, Yong-Mi Choi

Curr Med Chem· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small molecule glucokinase activators as glucose lowering agents: a new paradigm for diabetes therapy.
Kevin R Guertin, Joseph Grimsby

Curr Med Chem· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of a novel class of orally active pyrimido[5,4-3][1,2,4]triazine-5,7-diamine-based hypoglycemic agents with protein tyrosine phosphatase inhibitory activity.
Kevin R Guertin, Lina Setti, Lida Qi, Rachel M Dunsdon, Brian W Dymock

Bioorg Med Chem Lett· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allosteric activators of glucokinase: potential role in diabetes therapy.
Joseph Grimsby, Ramakanth Sarabu, Wendy L Corbett, Nancy-Ellen Haynes, Fred T Bizzarro, Kevin R Guertin

Science· July 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of the beta-aminoester class of factor Xa inhibitors. Part 1: P(4) and side-chain modifications for improved in vitro potency.
Mark Czekaj, Scott I Klein, Kevin R Guertin, Charles J Gardner, Allison L Zulli

Bioorg Med Chem Lett· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of the beta-aminoester class of factor Xa inhibitors. Part 2: Identification of FXV673 as a potent and selective inhibitor with excellent In vivo anticoagulant activity.
Kevin R Guertin, Charles J Gardner, Scott I Klein, Allison L Zulli, Mark Czekaj

Bioorg Med Chem Lett· June 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis